RTC
AZN icon

Riverview Trust Company’s AstraZeneca AZN Stock Holding History

Riverview Trust Company’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130
Closed -$23.9K – 205
2025
Q4 		$23.9K Hold
130
– – 0.03% 154
2025
Q3 		$19.9K Hold
130
– – 0.02% 165
2025
Q2 		$18.2K Hold
130
– – 0.02% 179
2025
Q1 		$19.1K Hold
130
– – 0.02% 444
2024
Q4 		$17K Hold
130
– – 0.02% 527
2024
Q3 		$20.3K Buy
+130
New +$21K 0.02% 471
2019
Q2 		– Sell
-56
Closed -$5K – 282
2019
Q1 		$5K Buy
+56
New +$4.41K ﹤0.01% 279

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

Riverview Trust Company's AZN Position: Q1 2026 in Review

Riverview Trust Company sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 130 shares — an estimated $23.9K sold.

Riverview Trust Company first reported a position in AZN in Q1 2019 and held it in 7 quarters. The position peaked at $23.9K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Riverview Trust Company reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Riverview Trust Company sold 130 AstraZeneca shares in Q1 2026, an estimated $23.9K.
  • Riverview Trust Company first reported a position in AstraZeneca in Q1 2019 and held it in 7 quarters.
  • Riverview Trust Company's AstraZeneca position peaked at $23.9K in Q4 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Riverview Trust Company's 13F filing for Q1 2026, filed 1 May 2026.